Conference abstractPublished 26 Oct 2015
AVX-470, an Orally-Delivered GI-Targeted anti-TNF Biobetter
Avaxia Biologics, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Avaxia Biologics is a clinical-stage biopharmaceutical company developing gut-targeted biobetter therapeutics. TNF is a clinically validated target in gut inflammation. Discussion will center on Avaxia’s orally-delivered, minimally absorbed anti-TNF biologic drug that acts locally in the GI tract. In contrast to first generation systemically delivered anti-TNFs, AVX-470 has low systemic exposure for greater safety, higher local concentration to drive efficacy, and the convenience of oral administration.
Subjects
Dentistry & Oral HealthAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDentistry & Oral Health
- BylineArticles whose byline prints “Neil Schauer”